RA: One JAK to Rule Them All?

Dr. Brian Jaros reports on abstract 1362, presented at the 2024 ACR Convergence meeting in Washington, DC.

Join The Discussion

eugene fung

| Nov 16, 2024 11:26 pm

Permalink

The article was done by Manufacturer , and the comparison is Upa and "others "
There are thousand of Upa vs Hundred and even 2 perficitinib
The initiation of Moderate activity in Upa 63% others 51%

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.